818 related articles for article (PubMed ID: 26701853)
41. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.
Zhou ZQ; Zhao JJ; Chen CL; Liu Y; Zeng JX; Wu ZR; Tang Y; Zhu Q; Weng DS; Xia JC
Mol Carcinog; 2019 Jan; 58(1):76-87. PubMed ID: 30182378
[TBL] [Abstract][Full Text] [Related]
42. Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.
Ezaka K; Kanda M; Sugimoto H; Shimizu D; Oya H; Nomoto S; Sueoka S; Tanaka Y; Takami H; Hashimoto R; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1499-507. PubMed ID: 26122373
[TBL] [Abstract][Full Text] [Related]
43. PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma.
Zhang L; Jia G; Shi B; Ge G; Duan H; Yang Y
Cell Physiol Biochem; 2016; 40(3-4):757-769. PubMed ID: 27915333
[TBL] [Abstract][Full Text] [Related]
44. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
45. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
46. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
[TBL] [Abstract][Full Text] [Related]
47. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
[TBL] [Abstract][Full Text] [Related]
48. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
49. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
50. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma.
Zha TZ; Hu BS; Yu HF; Tan YF; Zhang Y; Zhang K
Tumour Biol; 2012 Dec; 33(6):2125-34. PubMed ID: 22864671
[TBL] [Abstract][Full Text] [Related]
52. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
53. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
54. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma.
Hayashi M; Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Takeda S; Kodera Y
J Surg Oncol; 2012 Mar; 105(4):381-6. PubMed ID: 22052684
[TBL] [Abstract][Full Text] [Related]
55. Study on the relationship between the RASSF10 gene and the biological behavior of hepatocellular carcinoma cells.
Xie J; Chen Y; Meng F; Shu T; Liu Y; Zhang L; Zhang ZX
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3576-3580. PubMed ID: 28925496
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
Hu BS; Xiong SM; Li G; Li JP
Tumour Biol; 2016 Oct; 37(10):13445-13453. PubMed ID: 27465549
[TBL] [Abstract][Full Text] [Related]
57. Reduced expression of DACT2 promotes hepatocellular carcinoma progression: involvement of methylation-mediated gene silencing.
Gao S; Yang Z; Zheng ZY; Yao J; Zhang F; Wu LM; Xie HY; Zhou L; Zheng SS
World J Surg Oncol; 2013 Mar; 11():57. PubMed ID: 23496880
[TBL] [Abstract][Full Text] [Related]
58. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
[TBL] [Abstract][Full Text] [Related]
59. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
60. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
